



In vitro diagnostic kit

Infliximab ELISA



Advanced Practical Diagnostics BV
Raadsherenstraat 3, 2300 Turnhout, Belgium
Tel. +32 14 45 35 99 – <https://www.apdiagroup.com>

Infliximab ELISA IVD

REF 710001

The Infliximab ELISA is an enzyme linked immunosorbent assay intended for the quantitative determination of infliximab (IFX, Remicade[®], anti-TNF-alpha) in human serum and plasma.

1. BACKGROUND AND DIAGNOSTIC VALUE

Therapeutic Drug Monitoring

Infliximab (IFX) is a chimeric antibody that targets the pro-inflammatory cytokine TNF-alpha. The introduction of infliximab has revolutionized the treatment of chronic inflammatory diseases like inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and spondyloarthritis. It has been shown that infliximab can induce deep remission and improve the patient's quality of life¹. Some patients do not respond to IFX therapy upon induction (primary non-responders), while others lose response over time (secondary non-responders²).

A drug can only exert its pharmacologic effect when adequate concentrations are achieved in the circulation. The serum concentration of infliximab just before the next infusion, defined as the trough concentration, has been used for therapeutic drug monitoring (TDM). Recent data on TDM have shown that a good clinical response is associated with adequate trough concentrations in IBD³ and RA^{4,5} patients. TDM may therefore be very instrumental to optimize treatment and to overcome secondary loss of response.

The Infliximab ELISA uses a highly specific monoclonal antibody – clone 6B7, developed at the KU Leuven - that only detects infliximab (Remicade[®]). Other anti-TNF drugs (like adalimumab, golimumab) do not interfere with the measurement⁶. Biosimilars of Remicade[®] (Remsima[®], Inflectra[®], Flixabi[®]) are equally well quantified in the Infliximab ELISA of Advanced Practical Diagnostics BV⁷. As an example of TDM, the use of infliximab trough concentration measurements in inflammatory bowel disease patients is described.

Inflammatory bowel disease

Infliximab is given at week 0, week 2 and week 6 (induction) and upon good clinical response at week 14, treatment is continued by infusions every 8 weeks (maintenance). The diagnostic value of therapeutic drug monitoring in IBD patients is described hereunder for both the induction as well as the maintenance phase.

Induction phase: It has been demonstrated that postinduction IFX trough concentrations (week 14) are associated with a sustained clinical response^{8,9}. Infliximab trough concentration measurements during or shortly after induction may thus be used to identify undertreated patients and dose-optimize them.

Maintenance phase: It has been shown that patients on maintenance therapy having sustained trough concentrations, are more likely to remain in remission than patients with undetectable trough concentrations¹⁰. Thus, regularly checking IFX trough concentrations during maintenance therapy may be useful to evaluate the IFX treatment schedule and make adjustments when necessary. On top, it has been shown that patients on maintenance therapy who lost response to infliximab have more benefit from individualized treatment based on the measured IFX serum concentrations than from an empirical strategy that uses all other available therapeutic options¹¹.

Due to the dosing regimen, trough concentrations during induction w2 and w6 are higher and serum samples need to be diluted more compared to the maintenance phase in which trough concentrations between 0.5-12 µg/ml are common.

Immunogenicity

Secondary loss of response is often due to the development of anti-drug antibodies, because of the immunogenic character of the drug¹². In the case of undetectable trough concentrations, subsequent measurement of anti-drug antibodies may be helpful to determine the optimal treatment strategy.

2. PRINCIPLE OF THE INFLIXIMAB ELISA

Microtiterstrips coated with TNF-alpha are incubated with calibrators, controls and diluted patient samples. During this incubation step IFX binds specifically to the TNF-alpha on the solid phase. After removal of the unbound serum proteins by a washing procedure, the antigen-antibody complex in each well is detected with specific peroxidase-conjugated monoclonal antibody (clone 6B7, developed at the KU Leuven) directed to IFX.

After removal of the unbound conjugate, the strips are incubated with a chromogenic solution containing tetramethylbenzidine and hydrogen peroxide: a blue colour develops in proportion to the amount of immunocomplex bound to the wells of the strips. The enzymatic reaction is stopped by the addition of 0.5M H₂SO₄ and the absorbance values at 450 nm are determined.

A standard curve is obtained by plotting the absorbance values versus the corresponding calibrator values. The concentration of IFX in patient samples is determined by interpolation from the calibration curve.

3. REAGENTS

| Component | Name + Symbol |
|--|--|
| 1 coated microtiter plate (12 x 8 strips) | Precoated Strips |
| Strips coated with human TNF-alpha. | MTP |
| 6 vials, 1300 µl, ready-to-use | Calibrator |
| Each vial contains a ready-to-use calibrator solution, N having following values: CAL 0: 0 ng/ml; CAL 5: 5 ng/ml; CAL 10: 10 ng/ml; CAL 20: 20 ng/ml; CAL 60: 60 ng/ml; CAL 120: 120 ng/ml. Contain 0,09 % NaN ₃ . Calibrated against the WHO International Standard for Infliximab 16/170 ¹³ . | CAL N |
| 1 vial, 1300 µl, ready-to-use | Positive Control 1 |
| Positive Control for IFX, level 1; contains 30 ng/ml IFX. Contains 0.09% NaN ₃ . | CTL1 |
| 1 vial, 1300 µl, ready-to-use | Positive Control 2 |
| Positive Control for IFX, level 2; contains 70 ng/ml IFX. Contains 0.09% NaN ₃ . | CTL2 |
| 1 bottle, 100 ml, ready-to-use | Sample Diluent |
| Sample dilution buffer Contains 0.09% NaN ₃ and an inert orange dye. | DILSAM |
| 1 bottle, 12 ml, ready-to-use | Conjugate |
| Contains peroxidase conjugated monoclonal anti-IFX clone 6B7 antibodies. Contains antimicrobial agents and an inert red dye. | CONJ |
| 1 vial, 12 ml, ready-to-use | Chromogen Solution |
| Contains a solution of substrate (H ₂ O ₂) and chromogen (tetramethylbenzidine). | CHROM |
| 1 bottle, 50 ml, 20x concentrated | Wash Solution |
| Contains detergent in phosphate buffered solution and antimicrobial agents. | WASH 20x |
| 1 bottle, 6 ml, ready-to-use | Stop Solution |
| Consists of 0.5 M H ₂ SO ₄ . | STOP |
| 2 plate covers | - |


4. MATERIALS REQUIRED BUT NOT SUPPLIED

- Precision micropipettes and standard laboratory pipettes.
- Clean standard laboratory volumetric glassware.
- Clean glass or plastic tubes for the dilution of the samples.
- A microtiterplate reader capable of measuring absorbances at 450 nm.

5. WARNINGS AND PRECAUTIONS FOR USERS

- For *in vitro* diagnostic use only.
- Do not mix reagents or coated microtiterstrips from kits with different lot numbers.
- Stop Solution is a 0.5 M H₂SO₄ solution which is irritant. In case of contact with eyes or skin, rinse with plenty of water and seek medical advice.
- Chromogen Solution contains the hazardous ingredient N-Methyl-2-pyrrolidone at a concentration > 0,3 %. It is classified as a Reproductive Toxicant Category 1B. Following hazard statements are applicable:
H360D: May damage the unborn child.
Following precautionary statements are applicable:
P280: Wear protective gloves/protective clothing/eye protection/face protection.
P308+P313: IF exposed or concerned: Get medical advice/attention.
- Some kit components contain sodium azide as a preservative. In order to prevent the formation of potentially explosive metal azides in laboratory plumbing, flush drains thoroughly after disposal of these solutions.
- Although it might be advised to run calibrators/controls and samples in duplicate, reliable results are equally obtained by doing the analysis in singlicate.

6. STORAGE CONDITIONS



1. Store the microtiterstrips in their original package with the desiccant until all the strips have been used.
2. Opened components should be stored at 2-8°C until next use and can be maintained for 6 months.
3. Never use any kit components beyond the expiration date.

7. SPECIMEN COLLECTION AND PREPARATION

EDTA plasma, citrate plasma and serum samples may be used in this assay. It is recommended to use the serum tubes with clot activator and gel separator (e.g. BD Vacutainer SST II Advance). Remove serum from clot as soon as possible to avoid haemolysis. Transfer the serum to a clean storage tube. Specimens may be stored at 2-8 °C for 3-4 days, or they can be stored frozen for at least one year. Avoid repeated freezing and thawing. Samples must be diluted in Sample Diluent, see chapter 9.

8. ASSAY PROCEDURE

8.1 General Remarks

1. Use a separate disposable tip for each sample transfer to avoid cross-contamination.
2. All reagents must be allowed to come to room temperature before use. All reagents must be mixed without foaming.
3. Once the assay has been started, all steps should be completed without interruption.
4. The use of an ELISA Washer is recommended, however depending on the apparatus it may be necessary to adapt the washing procedure for obtaining optimal results.
5. The Infliximab ELISA may be used on any open ELISA automate after validation. Depending on the reader capacity of the instrument, it might be required to reduce the incubation time for the Chromogen Solution from 10 to 6 minutes (applicable for Dynex DS2 and Dynex DSX instruments). For instructions on how to perform the assay with ELISA instruments, please contact the manufacturer.

8.2 Reconstitution of Reagents

Washing Solution: dilute 50 ml of concentrated Washing Solution to 1000 ml with distilled water. Reconstituted solution can be stored at least 1 month, store at 2-8 °C. At higher temperatures, the concentrated Washing Solution may appear cloudy without affecting its performance. Upon dilution, the solution will be clear.

8.3 Assay Procedure

Before starting the assay, dilute the patient samples according to the guidelines in chapter 9.

1. Pipette 100 µl of the calibrators, controls and diluted samples into the wells.
2. Incubate the covered microtiterstrips for 60 ± 2 min at 37 °C (± 2 °C).
3. Empty the wells entirely by aspiration. Fill the wells completely with 350-400 µl of reconstituted washing solution, avoiding overflow of buffer from one well to another. Repeat the washing procedure two more times for a total of three washes. Finally, aspirate the content of the wells and remove any residual liquid by gently tapping the inverted wells on clean absorbent paper. Incomplete washing will adversely affect the test outcome.
4. Add 100 µl of Conjugate Solution and incubate the covered microtiterstrips for 30 ± 2 min at 37 °C (± 2 °C).
5. Repeat the washing procedure as described in 3.
6. Add 100 µl of Chromogen Solution to each well.
7. Incubate for 10 ± 1 min at 37 °C (± 2 °C). Avoid light exposure during this step.
8. Add 50 µl of Stopping Solution to each well.
9. Determine the absorbance of each well at 450 nm or at 450 nm with reference filter 600-650 nm within 30 min following the addition of acid.

9. SAMPLE DILUTION FACTOR

For measuring trough concentrations (samples taken just before next infusion) during maintenance phase (= from week 14 onwards), dilute samples 1:100.

Example: add 10 µl patient sample to 990 µl Sample Diluent

For measuring trough concentrations during induction phase (= at week 2 and at week 6) or for measuring intermediate concentrations, dilute samples 1:400.

Example: add 10 µl patient sample to 390 µl Sample Diluent = solution 1; subsequently add 100 µl of solution 1 to 900 µl Sample Diluent.

The dilution factor must be taken into account when calculating IFX concentration in the samples by multiplying the measured concentration by the dilution factor.

For calculating the IFX concentration in the controls, the same multiplicity factor must be used as for the samples. Concentration is then expressed in µg/ml.

Example: the outcome of 1:100 diluted sample, obtained by interpolation from the calibration curve is 60 ng/ml. The corresponding IFX concentration in the undiluted sample is then 6 µg/ml.

By diluting the samples 1:100, IFX concentrations between 0.5 and 12 µg/ml can be determined. By diluting the samples 1:400, IFX concentrations between 2.0 and 48 µg/ml can be determined.

Example: the outcome of 1:400 diluted sample, obtained by interpolation from the calibration curve is 60 ng/ml. The corresponding IFX concentration in the undiluted sample is then 24 µg/ml.

Diluted samples may be stored for at least 8 HR.

10. RESULTS

The average absorbance value of each calibrator is plotted against the corresponding IFX value and the best calibration curve (e.g. quadratic regression) is constructed. Use the average absorbance of each patient sample obtained in the IFX ELISA to determine the corresponding value by simple interpolation from the curve. Multiply the obtained value by the dilution factor.

Depending on the experience and/or availability of software, other methods of data reduction may be used.

11. PERFORMANCE CHARACTERISTICS

Example of typical optical density (OD) values:

| CALIBRATOR | OD |
|------------|-------|
| CAL 0 | 0.007 |
| CAL 5 | 0.104 |
| CAL 10 | 0.212 |
| CAL 20 | 0.453 |
| CAL 60 | 1.357 |
| CAL 120 | 2.508 |

Precision

Intra-assay variation (n=21; 1 run)

| | Level 1 | Level 2 | Level 3 | Level 4 |
|--------------|------------|------------|------------|------------|
| Mean (µg/ml) | 0.61 | 1.12 | 3.20 | 7.67 |
| SD | 0.040 | 0.052 | 0.152 | 0.521 |
| % CV | 6.6 | 4.6 | 4.8 | 6.8 |

Inter-assay variation (n=15; 5 runs)

| | Level 1 | Level 2 | Level 3 | Level 4 |
|--------------|------------|------------|------------|------------|
| Mean (µg/ml) | 0.77 | 1.58 | 4.17 | 9.82 |
| SD | 0.042 | 0.085 | 0.155 | 0.943 |
| % CV | 5.4 | 5.4 | 3.7 | 9.6 |

Specificity – normal human serum/plasma

Specificity has been evaluated by testing 72 healthy donor samples from Belgian origin. None of the samples showed a detectable concentration of IFX, resulting in a specificity of 100 %.

Specificity – interference

A panel of 30 potentially interfering samples was tested consisting of HAMA positive, lipemic, high bilirubin, high cholesterol, haemolysed and 1st semester pregnant women samples. No interaction with the investigated factors was observed.

Correlation with Reference Assay

Two clinical sample panels of 102 and 30 specimens respectively were analysed using the Infliximab ELISA and results were compared with data obtained using the IFX ELISA developed at the KU Leuven which served as reference assay. Pearson r values as indicator for the correlation between both assays were 0.95 and 0.97 respectively.

Minimal detectable concentration

The minimal detectable concentration of IFX is lower than 1 ng/ml. Taking into account a dilution factor of 1:100 this corresponds to 0.1 µg/ml.

Test validity

The following specifications must be met for each run to be valid:

OD value for the zero calibrator: < 0.080
OD value for the highest value calibrator: > 1.400

If multiplicity factor of 1:100 is applicable:

Concentration value for positive control CTL1: 3 µg/ml, range 2 – 4 µg/ml

Concentration value for positive control CTL2: 7 µg/ml, range 5 – 10 µg/ml

If multiplicity factor of 1:400 is applicable:

Concentration value for positive control CTL1: 12 µg/ml, range 8 – 16 µg/ml

Concentration value for positive control CTL2: 28 µg/ml, range 20 – 40 µg/ml

If one of the specifications is not met, the test run should be repeated.

12. TROUBLE SHOOTING

In case of high background signal (OD CAL0 > 0.08), the washing was insufficient. Repeat the test with more vigorous washing (increased number of cycles, soak time).

REFERENCES

1. Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. *Clin Exp Gastroenterol* 2009;2:101-9.
2. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. *Am J Gastroenterol* 2011;106:685-98.
3. Vermeire S, Gils A. Value of drug level testing and antibody assays in optimising biological therapy. *Frontline Gastroenterol* 2013;41-3.
4. Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. *Arthritis Res Ther* 2011;13:R105.
5. Mulleman D, Meric JC, Paintaud G, et al. Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. *Arthritis Res Ther* 2009;11:R178.
6. Van Stappen T, Brouwers E, Tops S, et al. Generation of a highly specific monoclonal antibody standard for harmonization of TNF-coated infliximab assays. *Ther Drug Monit* 2015 doi: 10.1097/FTD.0000000000000162
7. Gils et al. The biosimilars of infliximab are equally well quantified in a clinically validated infliximab assay. Posterabstract. *Ecco* 2015: P040.
8. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. *Gut* 2014.
9. Vande Castele N, Ballet V, Van Assche G, Rutgeerts P, Vermeire S, Gils A. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. *Gut*. England 2012;321; author reply 2.
10. Maser EA, Vilella R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. *Clin Gastroenterol Hepatol*. United States 2006;1248-54.
11. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. *Gut* 2013.
12. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *N Engl J Med*. United States: 2003 Massachusetts Medical Society; 2003:601-8.
13. Metcalfe C, Dougall T, Bird C, Rigsby P, Behr-Gross ME, Wadhwa M et al. The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity. *mAbs* 2019; 11:1, 13-25.

IFX11-21

Version history

| Version number | Description |
|----------------|--|
| IFX04-20 | Previous version |
| IFX11-21 | Writing in full the manufacturer name, according to its legal status: Advanced Practical Diagnostics BV instead of the abbreviation apDia. |